Altimmune, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2027 Annual Meeting of Stockholders: Catherine Sohn, Pharm D

Altimmune, Inc.’s own tally for this item (“Elect Director: Catherine Sohn, Pharm D”): 45,298,692 for, 7,116,089 withheld, per its Form 8-K filed April 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 19,599,242 for, 31,237 withheld, 21 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2027 Annual Meeting of Stockholders: Diane Jorkasky, M.D.

Altimmune, Inc.’s own tally for this item (“Elect Director: Diane Jorkasky, M.D.”): 45,332,124 for, 7,082,657 withheld, per its Form 8-K filed April 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 19,606,198 for, 24,282 withheld, 20 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2027 Annual Meeting of Stockholders: Jerome Durso

Altimmune, Inc.’s own tally for this item (“Elect Director: Jerome Durso, Chairman”): 47,577,875 for, 4,836,906 withheld, per its Form 8-K filed April 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 19,599,236 for, 31,250 withheld, 14 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2027 Annual Meeting of Stockholders: John M. Gill

Altimmune, Inc.’s own tally for this item (“Elect Director: John M. Gill”): 46,242,497 for, 6,172,284 withheld, per its Form 8-K filed April 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 19,588,074 for, 42,408 withheld, 18 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2027 Annual Meeting of Stockholders: Mitchel Sayare, Ph.D.

Altimmune, Inc.’s own tally for this item (“Elect Director: Mitchel Sayare, Ph.D.”): 45,194,158 for, 7,220,623 withheld, per its Form 8-K filed April 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 19,595,027 for, 35,453 withheld, 20 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2027 Annual Meeting of Stockholders: Philip L. Hodges

Altimmune, Inc.’s own tally for this item (“Elect Director: Philip L. Hodges”): 45,094,369 for, 7,320,412 withheld, per its Form 8-K filed April 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 19,590,924 for, 39,555 withheld, 22 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2027 Annual Meeting of Stockholders: Teri Lawver

Altimmune, Inc.’s own tally for this item (“Elect Director: Teri Lawver”): 44,926,060 for, 7,488,721 withheld, per its Form 8-K filed April 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 19,599,241 for, 31,237 withheld, 22 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2027 Annual Meeting of Stockholders: Wayne Pisano

Altimmune, Inc.’s own tally for this item (“Elect Director: Wayne Pisano”): 45,114,119 for, 7,300,662 withheld, per its Form 8-K filed April 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 19,461,529 for, 142,356 withheld, 26,615 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: Vote to elect the ten nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2026 Annual Meeting of Stockholders: Vipin K. Garg, Ph.D.

Altimmune, Inc.’s own tally for this item (“Elect Director: Vipin K. Garg, Ph.D.”): 17,425,330 for, 4,411,657 withheld, per its Form 8-K filed September 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 4,145,122 for, 11,016 withheld, 68 abstained.

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

Description as filed by funds: Vote to elect the ten nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2026 Annual Meeting of Stockholders: Catherine Sohn, Pharm D

Altimmune, Inc.’s own tally for this item (“Elect Director: Catherine Sohn, Pharm D”): 14,454,283 for, 7,382,704 withheld, per its Form 8-K filed September 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 66% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 2,545,722 for, 383,691 withheld, 1,214,993 abstained.

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

Description as filed by funds: Vote to elect the ten nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2026 Annual Meeting of Stockholders: Diane Jorkasky, M.D.

Altimmune, Inc.’s own tally for this item (“Elect Director: Diane Jorkasky, M.D.”): 14,778,350 for, 7,058,637 withheld, per its Form 8-K filed September 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 68% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 3,762,053 for, 336,568 withheld, 35,477 abstained.

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

Description as filed by funds: Vote to elect the ten nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2026 Annual Meeting of Stockholders: Klaus O. Schafer, M.D., MPH

Altimmune, Inc.’s own tally for this item (“Elect Director: Klaus O. Schafer, M.D., MPH”): 14,643,908 for, 7,193,079 withheld, per its Form 8-K filed September 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 67% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 3,771,787 for, 337,074 withheld, 35,545 abstained.

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

Description as filed by funds: Vote to elect the ten nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2026 Annual Meeting of Stockholders: Philip L. Hodges

Altimmune, Inc.’s own tally for this item (“Elect Director: Philip L. Hodges”): 14,680,278 for, 7,156,709 withheld, per its Form 8-K filed September 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 67% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 3,761,479 for, 337,074 withheld, 35,545 abstained.

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

Description as filed by funds: Vote to elect the ten nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2026 Annual Meeting of Stockholders: Jerome Durso

Altimmune, Inc.’s own tally for this item (“Elect Director: Jerome Durso, Chairman”): 20,607,586 for, 1,229,401 withheld, per its Form 8-K filed September 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 4,125,720 for, 3,555 withheld.

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

Description as filed by funds: Vote to elect the ten nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2026 Annual Meeting of Stockholders: John M. Gill

Altimmune, Inc.’s own tally for this item (“Elect Director: John M. Gill”): 18,050,621 for, 3,786,366 withheld, per its Form 8-K filed September 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 4,069,993 for, 59,214 withheld, 68 abstained.

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

Description as filed by funds: Vote to elect the ten nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2026 Annual Meeting of Stockholders: Mitchel Sayare, Ph.D.

Altimmune, Inc.’s own tally for this item (“Elect Director: Mitchel Sayare, Ph.D.”): 17,619,208 for, 4,217,779 withheld, per its Form 8-K filed September 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 4,069,993 for, 59,214 withheld, 68 abstained.

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

Description as filed by funds: Vote to elect the ten nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2026 Annual Meeting of Stockholders: Teri Lawver

Altimmune, Inc.’s own tally for this item (“Elect Director: Teri Lawver”): 16,535,619 for, 5,301,368 withheld, per its Form 8-K filed September 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 4,125,720 for, 3,555 withheld.

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

Description as filed by funds: Vote to elect the ten nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2026 Annual Meeting of Stockholders: Wayne Pisano

Altimmune, Inc.’s own tally for this item (“Elect Director: Wayne Pisano”): 18,052,060 for, 3,784,927 withheld, per its Form 8-K filed September 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 4,070,001 for, 59,206 withheld, 68 abstained.

Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.

Description as filed by funds: Vote to elect the nine nominees named in the attached Proxy Statement as members of the Company's Board of Directors for terms expiring at the 2027 Annual Meeting of Stockholders: Klaus O. Schafer, M.D., MPH

Altimmune, Inc.’s own tally for this item (“Elect Director: Klaus O. Schafer, M.D., MPH”): 44,722,328 for, 7,692,453 withheld, per its Form 8-K filed April 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 37 asset managers below reported 16,026,385 for, 34,841 withheld.

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

Description as filed by funds: VOTE TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF THE COMPANY'S COMMON STOCK.

Altimmune, Inc.’s own tally for this item (“4. Vote to approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended to increase the number of authorized shares of the Company's common stock from 200,000,000 to 400,000,000”): 63,684,172 for, 24,151,522 against, per its Form 8-K filed April 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 73% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 19,606,170 for, 24,329 against.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: APPROVE THE AUTHORIZATION TO ADJOURN THE ANNUAL MEETING, IF NECESSARY OR APPROPRIATE, TO SOLICIT ADDITIONAL PROXIES IN FAVOR OF THE FOREGOING PROPOSALS IF THERE ARE NOT SUFFICIENT VOTES TO APPROVE THE PROPOSALS.

Altimmune, Inc.’s own tally for this item (“6. Vote to authorize the adjournment of the 2026 Annual Meeting to enable the Board of Directors to solicit additional proxies”): 68,318,332 for, 18,755,920 against, per its Form 8-K filed April 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 17,894,346 for, 1,711,872 against, 24,283 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: APPROVE THE AUTHORIZATION TO ADJOURN THE ANNUAL MEETING, IF NECESSARY OR APPROPRIATE, TO SOLICIT ADDITIONAL PROXIES IN FAVOR OF THE FOREGOING PROPOSALS IF THERE ARE NOT SUFFICIENT VOTES TO APPROVE THE PROPOSALS.

Altimmune, Inc.’s own tally for this item (“4. Vote to authorize the adjournment of the 2025 Annual Meeting to enable the Board of Directors to solicit additional proxies”): 33,695,815 for, 16,363,206 against, per its Form 8-K filed September 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 67% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 3,448,922 for, 636,966 against, 3,555 abstained.

Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.

Description as filed by funds: Vote to approve an amendment to the Company's 2019 Employee Stock Purchase Plan to increase the number of shares of the Company's common stock reserved under the Company's 2019 Employee Stock Purchase Plan.

Altimmune, Inc.’s own tally for this item (“5. Vote to approve an amendment to the Company's 2019 Employee Stock Purchase Plan (the "2019 ESPP") to increase the number of shares of the Company's common stock reserved under the 2019 ESPP from 403,500 to 1,108,827”): 43,616,919 for, 8,572,159 against, per its Form 8-K filed April 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 19,606,693 for, 24,307 against.

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

Description as filed by funds: HOLD AN ADVISORY VOTE ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE ATTACHED PROXY STATEMENT.

Altimmune, Inc.’s own tally for this item (“3. Advisory vote on the Compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules (referred to as the "say-on-pay" proposal)”): 39,928,184 for, 12,026,081 against, per its Form 8-K filed April 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 45 managers: 19,257,619 for, 348,598 against, 24,283 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 126 managers: 14,474,534 for, 2,933,401 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: HOLD AN ADVISORY VOTE ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE ATTACHED PROXY STATEMENT.

Altimmune, Inc.’s own tally for this item (“3. Advisory vote on the Compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules (referred to as the "say-on-pay" proposal)”): 14,885,881 for, 6,683,682 against, per its Form 8-K filed September 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 69% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 39 managers: 3,716,509 for, 309,411 against, 3,555 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 111 managers: 4,034,624 for, 2,873,547 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: VOTE TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.

Altimmune, Inc.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026”): 84,959,584 for, 1,771,538 against, per its Form 8-K filed April 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 19,606,163 for, 55 against, 24,283 abstained.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: VOTE TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2025.

Altimmune, Inc.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025”): 48,959,891 for, 1,355,769 against, per its Form 8-K filed September 25, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 4,152,643 for, 8 against, 3,555 abstained.

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.